High doses of daunorubicin during induction therapy of newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis of prospective clinical trials

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Gong, Qiang ^a   Zhou, Lixin ^a   Xu, Shuangnian ^a   Li, Xi ^a   Zou, Yunding ^a   Chen, Jieping ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; IDARUBICIN; ANTINEOPLASTIC ANTIBIOTIC;

ACUTE MYELOBLASTIC LEUKEMIA; BLEEDING; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; GASTROINTESTINAL TOXICITY; GENETIC RISK; HUMAN; INFECTION; LOW DRUG DOSE; META ANALYSIS; MUCOSA INFLAMMATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPTICEMIA; SYSTEMATIC REVIEW; LEUKEMIA, MYELOID, ACUTE; PROSPECTIVE STUDY;

ANTIBIOTICS, ANTINEOPLASTIC; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROSPECTIVE STUDIES;

EID: 84930642702     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125612     Document Type: Review

References (27)

1. Wang J, Yang YG, Zhou M, Xu JY, Zhang QG, Zhou RF, et al. Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia. 2013. p. e60699.
2. Roboz GJ. Novel approaches to the treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2011; 2011:43-50. doi: 10.1182/asheducation-2011.1.43 PMID: 22160011
3. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115:453-74. doi: 10.1182/blood-2009-07-235358 PMID: 19880497
4. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368:1894-907. PMID: 17126723
5. Lowenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2003:82-101. PMID: 14633778
6. Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27:61-9. doi: 10.1200/JCO.2007.15.4245 PMID: 19047294
7. Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol 2010; 28:586-95. doi: 10.1200/JCO.2009.22.9088 PMID: 20038732
8. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, Graf N, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood 2013; 122:37-43. doi: 10.1182/blood-2013-02-484097 PMID: 23704089
9. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline Dose Intensification in Acute Myeloid Leukemia. The New England Journal of Medicine 2009; 361:1249-59. doi: 10.1056/NEJMoa0904544 PMID: 19776406
10. Lee JH, Joo YD, Kim H, Bae SH, Kim MK, Zang DY, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 2011; 118:3832-41. doi: 10.1182/blood-2011-06-361410 PMID: 21828126
11. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361:1235-48. doi: 10.1056/NEJMoa0901409 PMID: 19776405
12. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 2011; 117:2358-65. doi: 10.1182/blood-2010-03-273243 PMID: 20693429
13. Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010; 28:808-14. doi: 10.1200/JCO.2009.23.2652 PMID: 20048183
14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. Int J Surg 2010; 8:336-41. doi: 10.1016/j.ijsu.2010.02.007 PMID: 20171303
15. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21:4642-9. PMID: 14673054
16. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8:16. PMID: 17555582
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-58. PMID: 12111919
18. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77:1666-74. PMID: 2015395
19. Mandelli F, Petti MC, Ardia A, Di Pietro N, Di Raimondo F, Ganzina F, et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. Eur J Cancer 1991; 27:750-5. PMID: 1829918
20. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 1992; 10:1103-11. PMID: 1607916
21. Wheatley K. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol 1998; 103:100-9. PMID: 9792296
22. Wiernik PH, Banks PL, Case DJ, Arlin ZA, Periman PO, Todd MB, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79:313-9. PMID: 1730080
23. Ziogas DC, Voulgarelis M, Zintzaras E. A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly. Clin Ther 2011; 33:254-79. doi: 10.1016/j.clinthera.2011.04.004 PMID: 21600383
24. Appelbaum FR, Dahlberg S, Thomas ED, Buckner CD, Cheever MA, Clift RA, et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. 1984. p. 581-8.
25. Castaigne S, Chevret S, Archimbaud E, Fenaux P, Bordessoule D, Tilly H, et al. Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: longterm analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 2004; 104:2467-74. PMID: 15142880
26. Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 2004; 22:4290-301. PMID: 15514371
27. Teuffel O, Leibundgut K, Lehrnbecher T, Alonzo TA, Beyene J, Sung L. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. British Journal of Haematology 2013; 161:192-203. doi: 10.1111/bjh.12233 PMID: 23398482